Trinity Biotech
TRIB
23 hedge funds and large institutions have $12.7M invested in Trinity Biotech in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 8 closing their positions.
315% more call options, than puts
Call options by funds: $141K | Put options by funds: $34K
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0% less ownership
Funds ownership: 0.05% → 0.05% (-0%)
12% less funds holding
Funds holding: 26 → 23 (-3)
20% less capital invested
Capital invested by funds: $15.9M → $12.7M (-$3.17M)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$796K |
| 2 |
Renaissance Technologies
New York
|
+$227K |
| 3 |
Morgan Stanley
New York
|
+$138K |
| 4 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$117K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$114K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
-$2.41M |
| 2 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$874K |
| 3 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$293K |
| 4 |
Goldman Sachs
New York
|
-$130K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$76K |
TRIB Hedge Fund Activity: Q3 2020 in Review
23 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q3 2020, worth a combined $12.7M — down 20% from $15.9M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of TRIB and 5 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Acadian Asset Management, adding an estimated $796K. The largest seller was Stonehill Capital Management, cutting an estimated $2.41M.
- 23 institutional investors held Trinity Biotech (TRIB) as of Q3 2020, down from 26 in Q2 2020.
- Funds reported $12.7M of Trinity Biotech stock for Q3 2020, down 20% quarter-over-quarter.
- 5 funds opened new Trinity Biotech positions in Q3 2020 and 8 closed out, a net change of -3 holders.
- The largest Trinity Biotech buyer in Q3 2020 was Acadian Asset Management, an estimated $796K added.
- The largest Trinity Biotech seller in Q3 2020 was Stonehill Capital Management, an estimated $2.41M sold.
Based on aggregated 13F filings for Q3 2020.